The FDA should back off of 23andMe and allow the firm to continue selling its consumer genomics service because it is unlikely to lead to unnecessary diagnostic tests and medical procedures, argues Forbes writer Frida Polli.
Registering provides access to this and other free content.
Already have an account?Login Now.
Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.
DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.
A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.
In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.